Copy from another poster I follower on IHUB, Flet
Post# of 1460
(Total Views: 364)
Posted On: 11/07/2017 12:46:34 PM
Copy from another poster I follower on IHUB,
Fletch
dadofmarcmax Tuesday, 11/07/17 12:39:08 PM
Re: kevindenver post# 129379
Post # of 129397
Speaking of ibuprofen.....you do know that it is a nonsteroidal anti-inflammatory drug (NSAID).
Did you also know that people with a higher exposure to ibuprofen in a lifetime have a lesser risk of developing Alzheimer's disease?
While certainly not proof that Alzheimer's is the result of an inflammatory process, this fact certainly points that this theory - that AD is related to chronic neuroinflammation - is likely to be reality.
Amyloid-beta plaques - are just biproducts of chronic neuroinflammation and getting rid of the plaques will do nothing to stop the upstream process that is causing neurodegeneration. This upstream process is neuroinflammation.
I consider Anavex 2-73, in essence, as an anti-inflammatory agent that works against chronic neuroinflammation - a complicated pathophysiological process that can lead to varied neurological pathologies in the old and young. Hence why Anavex 2-73 has so many applications potentially to seemingly different neurological conditions.
We essentially have one of the newest and potentially the most versatile anti-inflammatory agent that is non-steroidal in nature but not of the same MOA as other NSAIDs. This is a whole new class of anti-inflammatory agents, in my opinion only.
As a physician who often errs of the controversial side of the science spectrum, I am a believe that chronic neuroinflammation leads to many neurological disorders and by tackling this using unique agents like A-273 or other agents that act on the endocannabinoid system - we have tools to start tackling chronic inflammatory processes.
This is getting exciting!
BTW, I will be at AES (American Epilepsy Society) conference this year. Does anyone know if Anavex plans on attending?
Fletch
dadofmarcmax Tuesday, 11/07/17 12:39:08 PM
Re: kevindenver post# 129379
Post # of 129397
Speaking of ibuprofen.....you do know that it is a nonsteroidal anti-inflammatory drug (NSAID).
Did you also know that people with a higher exposure to ibuprofen in a lifetime have a lesser risk of developing Alzheimer's disease?
While certainly not proof that Alzheimer's is the result of an inflammatory process, this fact certainly points that this theory - that AD is related to chronic neuroinflammation - is likely to be reality.
Amyloid-beta plaques - are just biproducts of chronic neuroinflammation and getting rid of the plaques will do nothing to stop the upstream process that is causing neurodegeneration. This upstream process is neuroinflammation.
I consider Anavex 2-73, in essence, as an anti-inflammatory agent that works against chronic neuroinflammation - a complicated pathophysiological process that can lead to varied neurological pathologies in the old and young. Hence why Anavex 2-73 has so many applications potentially to seemingly different neurological conditions.
We essentially have one of the newest and potentially the most versatile anti-inflammatory agent that is non-steroidal in nature but not of the same MOA as other NSAIDs. This is a whole new class of anti-inflammatory agents, in my opinion only.
As a physician who often errs of the controversial side of the science spectrum, I am a believe that chronic neuroinflammation leads to many neurological disorders and by tackling this using unique agents like A-273 or other agents that act on the endocannabinoid system - we have tools to start tackling chronic inflammatory processes.
This is getting exciting!
BTW, I will be at AES (American Epilepsy Society) conference this year. Does anyone know if Anavex plans on attending?
(0)
(0)Anavex Life Sciences Corp. (AVXL) Stock Research Links
Scroll down for more posts ▼